Introduction {#S1}
============

The term "sher-pa" is the Tibetan for "eastern-people". The Sherpa reside primarily in the Solukhumbu district of Nepal but there are also smaller settlements in the Tibet Autonomous Region of China. The Sherpa speak a Tibetan dialect, and they share similar cultural and religious practices with Tibetans. They are traditionally engaged in farming; cultivating barley, potatoes and rearing yak and sheep. Starting with the first Everest expeditions in the 1920's, the Sherpa have become renowned for their ability as mountaineers and today they often aid and lead climbing expeditions in the Himalayas. Examples of their exceptional climbing feats include the first ascent of Mount Everest by Tenzing Norgay Sherpa, who accompanied Sir Edmund Hillary in the final stage of the 1953 expedition and Ang Rita Sherpa (known as "The Snow Leopard") who, between 1983 and 1996, summited Everest ten times without the use of supplemental oxygen. The remarkable tolerance of the Sherpa to hypoxia has, over the last 60 years, been a focus of attention for the scientific community, in particular physiologists ([@B48]).

The Sherpa are direct descendants of an ancestral population that has resided continuously on the Tibetan plateau for the past 25,000 to 40,000 years ([@B4]; [@B160]). This long exposure to the evolutionary pressure presented by high altitude has driven physiological adaptation, which in turn has allowed the Sherpa to thrive. The adaptive physiological makeup of the Sherpa can inform on treatments for hypoxia-related illness including pulmonary, cardiac, neurological and renal disorders ([@B96]; [@B92]; [@B47]). Thus, studying the Sherpa at altitude offers a unique, "natural laboratory" that can provide insight to the molecular mechanisms of hypoxia.

An early paper on Sherpa physiology, published in 1965, suggested that the Sherpa have an efficient mechanism of oxygen utilization at the cellular level, allowing them to perform well under hypoxia ([@B80]). Since then, our knowledge of Sherpa adaptation has grown, largely by comparing different physiological parameters between the Sherpa and people of lowland origin. With the development of high throughput DNA genotyping and sequencing platforms, genomic studies of indigenous high-altitude populations, including the Sherpa, have begun to emerge. These have provided insight into population history and genetic signatures of altitude-driven natural selection. In this review, we (1) summarize the population history of, (2) describe distinct adaptive phenotypes and (3) discuss signatures of selection, in the Sherpa. We highlight the need for further research connecting genetic factors to physiological adaptation in the Sherpa at extreme altitude.

The Sherpa, a Recently Derived Tibetan Population {#S2}
=================================================

Stone tools used by early humans have been found at Nwya Devu in central Tibet at an altitude of 4,600 m. Dating to 30,000 to 40,000 years before present (YBP), these findings represent the earliest archeological record of human colonization of the Tibetan plateau ([@B160]). Genetic studies have suggested that the ancestors of both the Sherpa and Tibetans diverged from a Han Chinese population and arrived on the Tibetan plateau from lowland East Asia around 40,000 years ago ([@B117]; [@B72]).

The prevailing hypothesis is that, during the 16th century, the ancestors of the Sherpa migrated from Tibet to the Khumbu Valley of Nepal, driven by political and religious turmoil resulting from a Mongol invasion ([@B108]). The presence of Sherpa-specific mitochondrial DNA (mtDNA) lineages ([@B77]) in a Nepalese context, with an estimated age of less than 1,500 years and derived from Tibetans, further supports this hypothesis of a recent migration of the Sherpa to the Khumbu valley ([@B18]).

There is a long history of migration from the Tibetan plateau to Nepal. To illustrate, genomic analysis of human dental samples (dating to between 1,700 and 3,000 YBP) from a northern region of Nepal show strong affinity for contemporary Tibetans ([@B73]). Analysis of both autosomal data ([@B91]; [@B52]) and uniparental mtDNA and Y-chromosome markers ([@B18]) have shown the Sherpa and Tibetans to share relatively recent common ancestry. Tibetans also share recent common ancestry with other Nepalese populations including the Rai, Magar, Tamang, and Gurung ([@B33]). The Sherpa share more genetic affinity with these Tibeto-Burman speaking populations than with other Indo-Aryan populations of Nepal. However, the Sherpa are distinct from other Nepalese populations in that the Sherpa have elevated levels of runs of homozygosity ([@B33]), and illustrate very little or no admixture with Nepalese or South Asian populations ([@B33]). Thus, the Khumbu Valley Sherpa can be considered from the perspective of population genetics as a "bottlenecked" population recently derived from Tibetans.

Comparative Physiological Studies Between Sherpa and Lowlanders {#S3}
===============================================================

In 1952, Griffith Pugh conducted a series of pioneering physiological experiments on Mount Cho Oyo (at 8,188 m, 20 km west of Mount Everest) that suggested a superior work capacity of the Sherpa at high altitude ([@B116]; [@B115]). They also provided the scientific rationale for the hydration, nutrition and oxygen requirements for the first Everest summiting in 1953 ([@B98]). Although the physiology of the Sherpa has been studied over the intervening 60 years, the scientific literature is limited in number, and most of the studies are based on small sample sizes. There are obvious challenges to studying the Sherpa; they reside in a remote region, at an altitude over 2,800 m, where altitude sickness is common for sojourners. Despite this, several remarkable findings have emerged and below we discuss specific phenotypes that may be linked to hypoxia-related genetic signals of selection reported to date. For a discussion of other hypoxia-related physiological parameters studied in Sherpa, such as ventilation, lung volume, exercise capacity and cerebral function (see [@B48]; [Table 1](#T1){ref-type="table"}).

###### 

Physiological parameters studied in Sherpa and lowlanders at altitude.

  **Parameter(s)**                                                                                    **Sherpa at high altitude**                               **Lowlander at altitude (meter)**      **Reference(s)**                                                                                                         
  --------------------------------------------------------------------------------------------------- --------------------------------------------------------- -------------------------------------- ------------------ ------------------------------------- ---------------------------------- ---------------------------- ------------------------
  Heart rate while working at 900 kg⋅m/min-beats/min                                                  1                                                         162                                    5,800              2                                     240                                122                          [@B116]; [@B115]
  Lung diffusion capacity for oxygen-ml/min                                                           1                                                         97                                     5,800              2                                     240                                52.5                         [@B116]
  Basal metabolic rate, kcal/m^2^ h                                                                   3                                                         46.1 ± 1.0                             5,800              8                                     240                                41.1 ± 3.6                   [@B50]
  10 different physiological parameters; measured, to test oxygen utilization at the cellular level   ^4^                                                       efficiently used O~2~                  4,880              3                                     60                                 less efficient to use O~2~   [@B80]
  Heart rate (while work rate at 1,265 kg-m/min)- beats/min                                           4                                                         198                                    4,880              2                                     63                                 146                          [@B82]
  Partial pressure of carbon dioxide in the arterial blood, mm Hg                                     ^4^                                                       28.6                                   4,880              5                                     60                                 25.9                         [@B81]
  Hemoglobin level in Tibetans living at 3658 m in Nepal; g/l00 ml                                    52                                                        Male; 16.8 ± 1.4; Female: 14.5 ± 0.7                      --                                    [@B1]                                                           
  Hemoglobin level in Tibetans living at 4000 m in Nepal; g/l00 ml                                    51                                                        Male; 17.0 ± 1.25; Female:15.3 ± 0.8                      --                                    [@B2]                                                           
  Ratio of 2, 3 diphosphoglycerate and hemoglobin                                                     7                                                         0.9                                    3,900              2                                     30                                 1.26                         [@B104]
  Mean oxygen half saturation of hemoglobin                                                           7                                                         27.3 ± 1.8                             3,500              7                                     120                                28.2 ± 1.3                   [@B121]
  Arterial oxygen saturation (SaO~2~)                                                                 10                                                        88 ± 0.74                              4,243              25                                    12                                 85.6 ± 1.0                   [@B56]
  Body weight changes- Mean weight loss (kg)                                                          4                                                         constant                               5,400              13                                    25                                 1.9 to 4                     [@B24]
  Hypoxic ventilatory response (HVR)-end-tidal PO~2~, 40 Torr                                                                                                   6,300                                  9                  25                                    21.2 ± 5.4                         [@B126]                      
  Partial pressure of oxygen in arterial blood (Torr)                                                 6                                                         34.5 ± 3.2                             5,400              9                                     --                                 41.0 ± 3.3                   [@B122]
  Partial pressure of carbondioxide in arterial blood (Torr)                                          6                                                         27.5 ± 2.2                             5,400              9                                     --                                 20.0 ± 2.8                   [@B136]
  Hemoglobin oxygen affinity values                                                                   14                                                        29.8 ± 1.9                             --                 1                                     --                                 19                           [@B151]
  Resting glucose appearance rate at sea level (1.79 ± 0.02) mg.kg−l.min-1                            --                                                        --                                     4,300              7                                     21                                 3.59 ± 0.08                  [@B25]
  HVR shape parameter A, (mean ± SE)                                                                  27                                                        121 ± 17                               3,658              30                                    9 ± 1 year                         81 ± 10                      [@B161]
  Resting mean pulmonary arterial pressure SE mmHg                                                    5                                                         15 ± 1                                                    22                                                                       28 ± 2                       [@B54]
  Glucose metabolic rates of myocardial regions                                                       6                                                         0.32 ± 0.05                            226                6                                                                        0.20 ±0 04                   [@B63]
  Brain glucose metabolic rates                                                                       ^6^                                                       0.71                                                      6                                     19                                 0.73                         [@B62]
  Signs of mild cortical atrophy                                                                      7                                                         Seen in 1                                                 21                                                                       Seen in 13                   [@B44]
  Partial pressure of carbon dioxide, mm Hg                                                           5                                                         28.8 ± 1.2                             3,400              4                                     40                                 22.0 ± 0.4                   [@B120]
  Mean arterial blood pressure, mm Hg                                                                 9                                                         83 ± 6                                 4,243              10                                    7                                  94 ± 7                       [@B69]
  Forced expiratory volume of adult male (%)                                                          146                                                       110(107−114)                           3,840              103                                                                      103.8 (100.4-107.3)          [@B58]
  Heart Rate (beats min--1) means ± S.D.                                                              7                                                         167 ± 10                               5,050              10                                    28                                 149 ± 7                      [@B95]
  Carried loads of their body weight (mean ± SD)                                                      96                                                        93 ± 36%                               2,880              10                                                                       75%                          [@B11], [@B12], [@B10]
  Arterial oxygen saturation (SaO~2~) or (SpO~2~)                                                     --                                                        --                                     5,620              lower SaO*~2~* in Han than Tibetans   [@B152]; [@B153]                                                
  Arterial oxygen saturation, %                                                                       10                                                        88 ± 3                                 40                 10                                    97 ± 2                             [@B70]                       
  Statistically significant gender specific differences in SpO~2~                                     Adult Tibetan female show higher SpO~2~ value than male                                          [@B148]                                                                                                                  
  Serum angiotension-converling enzyme activity, IU/L/37°C                                            105                                                       14.5 ± 0.4                             1,300              111                                                                      14.7 ± 0.4                   [@B39]
  Mean arterial oxygen content at 8,400 m (26% lower than at 7100 m)                                  --                                                        --                                     8,400              4                                     --                                 145.8 ml per L               [@B53]
  Muscle phosphocreatine recovery halftime- PCr~tl/2~ (s)                                             7                                                         22.2 ± 1.6                             50                 7                                     --                                 16.1 ± 1.1                   [@B41]
  Radial arterial plasma NO~2~^--^(nmol I^--1^)                                                       --                                                        --                                     4,559              26                                    4                                  263.6 ± 61.2                 [@B8]
  Middle cerebral artery diameter \[at 6,400 m = 6.66 mm\]                                            --                                                        --                                     7,950              5                                     71                                 9.34 mm                      [@B150]
  Flow-mediated dilatation (FMD)-shear rate                                                           12                                                        24490 ± 7230                           5,050              12                                    14                                 14802 ± 5306                 [@B86]
  Arterial oxygen saturation (mean ± SE)                                                              13                                                        86 ± 1                                 5,050              13                                    9                                  83 ± 2                       [@B43]
  Hemoglobin level ml. min(−l). mmHg(−l)                                                              13                                                        61 ± 4                                 5,050              13                                    9                                  37 ± 2                       [@B43]
  Lung diffusing capacities                                                                           13                                                        226 ± 18                               5,050              13                                    9                                  153 ± 9                      [@B43]
  Systolic pulmonary artery pressure                                                                  95                                                        29.4 ± 5.5                             13                 64                                    --                                 23.6 ± 4.8                   [@B26]
  Left ventricular untwisting velocity, °/s                                                           11                                                        −93 ± 31                               5,050              9                                     13                                 −153 ± 38                    [@B134]
  Right ventricular isovolumic ralaxation time, ms                                                    11                                                        64 ± 20                                5,050              9                                     13                                 78 ± 14                      [@B135]
  No significant differences of dietary nitrate supplementation on AMS score                          --                                                        --                                     4,559              28                                    7                                  *p* = 0.29, *p* = 0.47       [@B34]
  Arterial oxygen saturation (%, 95% CI of Mean)                                                      --                                                        --                                     5,300              11                                    13                                 73.0 (70.3--75.5)            [@B93]
  Relative *PPARA* mRNA expression of muscles tissues                                                 15                                                        0.5158                                 5,300              10                                    19                                 1.0045                       [@B65]
  Post reproductive, Tibetan women (*n*=959)-Hemoglobin concentration, gm/dl                          ***--***                                                  13.8                                                                                            --                                 --                           [@B32]
  Increase in nocturnal time course of blood oxygen saturation level at rest                          --                                                        --                                     3,050              10                                    21                                 94.5% (91-97)                [@B142]
  FMD unchanged (in rest and maximal exercise), at low and high altitude                              --                                                        --                                     3,800              9                                     7                                  (6.3 ± 1.3)%                 [@B145]
  Brachial artery blood flow \[at Sea level- (142.7 ± 30.6)\], ml/min                                 --                                                        --                                     5,050              14                                    21                                 53.1 ± 11.1                  [@B146]
  Number of circulating microparticles in blood (CD 66b+)/μ1 (21 ± 4) Sea level                                                                                 --                                     3,800              10                                    3                                  74 ± 17                      [@B144]
  Birth-weight (kg) in Tibetans & Han; at 3,000--4,000 m altitude                                     100                                                       3.14 (3.06, 3.22)                      \<4,000            100                                                                      2.61 (2.34, 2.88)            [@B103]
  Case report of a 32 week gestation Sherpa at 5160 m and her data after 10 month postpartum          No apparent maternal, fetal or neonatal complications     --                                     [@B36]                                                                                                                   
  Arterial oxygen pressure (PaO~2~; mm Hg)                                                            --                                                        --                                     4,100              8                                     50                                 54 ±1.2                      [@B94]
  Prefatigue, maximal voluntary contraction torque, N. m                                              9                                                         50.1 ± 11.3                            5,050              9                                     --                                 --                           [@B119]
  Maximal voluntary contractile force (kg)                                                            10                                                        44.3 ± 14.1                            5,050              12                                    10                                 58.2 ± 8.1                   [@B118]
  Brachial artery flow-mediated dilation (FMD)                                                        12                                                        5.8 ± 2.8%                             5,050              22                                    10                                 3.8 ± 2.8%                   [@B143]
  Resting posterior cerebral artery velocity                                                          --                                                        --                                     4.240              10                                    13                                 43 cm/s                      [@B83]
  Lowland origin; Female SpO~2~; Mean (SD), (%)\[95.2 (1.2); at 600 m\]                               --                                                        --                                     3,500              20                                    1                                  76.7 (5.6)                   [@B28]
  Partial pressure of arterial carbon dioxide. mmHg                                                   11                                                        32.1 ±2.5                              5,050              21                                    21                                 30.0 ±1.9                    [@B149]
  Peripheral oxygen saturation in female \[at 600 m; 96.9 (1.0)\] Mean (SD) %                         --                                                        --                                     3,840              20                                    1                                  86.5 (6.5)                   [@B29]
  SpO~2~ (%) \[at Sea Level (244 m) is 98 ± 1\]                                                       --                                                        --                                     3.800              12                                    10                                 89.1 ± 3                     [@B133]
  Free cysteine and plasma total free thiol concentrations                                            --                                                        --                                     4,559              4                                     Elevated at 4,559 m than at 50 m   [@B35]                       
  Sublingual capillary total vessel density \[at Sea Level; 18.81 ± 3.92 mm mm^--2^                   --                                                        --                                     7,042              10                                    21                                 21.25 ±2.27                  [@B60]
  Sympathetic nerve activity, burst frequency (bursts min^--1^)                                       8                                                         22 ± 11                                5,050              14                                    20                                 30 ± 9                       [@B130]

Hemoglobin Concentration {#S3.SS1}
------------------------

The hypoxic challenge presented by high altitude drives changes in hemoglobin concentration. Elevated hemoglobin levels (≥19 g/dl in females; and ≥21 g/dl in males) resulting from hypoxia can lead to chronic mountain sickness ([@B84]). Relative to lowland controls, the literature suggests the Sherpa display lower hemoglobin concentrations at high altitude ([@B13]; [@B154]; [@B19]). Sherpa women with lower hemoglobin concentrations (13.8 g/dl ± 1.3 g/dl) are reported to have better reproductive outcomes ([@B17], [@B16]; [@B32]). Increased exercise capacity has been reported in Tibetan males with a low erythropoietic response ([@B128]). It is yet to be determined whether the lower hemoglobin concentration observed in Sherpa is due to a blunted erythropoietic response or to some other physiological parameters that impact hemoglobin concentration.

Nitric Oxide Concentration {#S3.SS2}
--------------------------

Nitric oxide acts as a vasodilator and is believed to protect against pulmonary hypertension at high altitude ([@B31]). It also plays a role in haematocrit regulation by controlling blood viscosity ([@B7]). Serum nitric oxide levels have been reported as reduced in the Sherpa relative to lowlanders ([@B38]), and a recent study reported no differences in circulating nitric oxide metabolites \[N-nitrosamine (RNNO), S-nitrosothiol, nitrate, or nitrite concentrations\] between Sherpa and lowlanders at both low and high altitude ([@B65]). However, a non-synonymous variant (rs549340789) in NOS1 (nitric oxide synthases 1) has been identified as under positive selection in the Sherpa ([@B159]). Thus, it seems that nitric oxide may play an important role in hypoxic adaptation ([@B42]; [@B15]), but the exact mechanisms remain poorly understood.

Microcirculation {#S3.SS3}
----------------

Lowlanders exhibit, in a hypoxic environment, reduced sublingual microcirculatory blood flow ([@B97]). However, the Sherpa maintain sublingual capillary densities and microcirculatory blood flow ([@B46]) at altitude. Compared to mountaineers of European-ancestry, during an expedition to Mount Everest, Sherpa exhibit elevated basal levels of angiogenic elements including vascular endothelial growth factor A (VEGF-A), interleukins (IL-8) and lymphangiogenic factors (VEGF-C and D), which likely facilitate increased microcirculatory flow ([@B110]). The Sherpa display an elevated oxygen unloading rate, and increased myogenic activity relative to lowlanders, further supporting higher peripheral microcirculatory perfusion ([@B37]). Following a defined period of induced leg occlusion and muscle ischemia, the Sherpa are reported to display increased blood flow velocity, relative to lowlanders ([@B125]). This is likely due to differences in conduit vessel function. Thus, the Sherpa appear to exhibit distinct microcirculation patterns, which might facilitate increased tissue oxygen transfer to overcome hypoxia.

Pulmonary and Cardiac Physiology {#S3.SS4}
--------------------------------

The Sherpa have greater spirometry values, forced expiratory volumes and forced vital capacity relative to lowlanders at high altitude ([@B116]; [@B58]). Lowlanders often experience apnea-induced brady-arrhythmias at high altitude, while Sherpa typically do not ([@B30]). The Sherpa display lower pulmonary vascular resistance and smaller left ventricular end-diastolic volume ([@B134]). However, the mechanism by which this reduced myocardial relaxation impacts on the exercise capacity of the Sherpa is unclear ([@B135]).

Evidence suggests a shift in cardiac substrate preference, from fat to glucose, in Sherpa relative to lowland controls ([@B63]). Some patients with heart failure display a reduction of the myocardial PCr to ATP ratio ([@B107]). Lowlanders returning from high altitude also display a significant decrease in myocardial PCr/ATP ratio ([@B64]), but this ratio remains steady in the Sherpa ([@B61]).

Skeletal Muscle {#S3.SS5}
---------------

Sherpa muscle contains a significantly greater number of capillaries per cross-sectional area, in comparison to lowlanders ([@B78]). Sherpa also display a reduced mitochondrial content, but their muscle is somehow maximizing the oxygen consumption to mitochondrial volume ratio ([@B78]; [@B65]). Under hypoxia, Sherpa skeletal muscle prefers carbohydrate over fatty acids as a metabolic substrate ([@B105]). Sherpa muscle maintains fatty acid oxidation relative to lowlanders at high altitude. Incomplete fatty acid oxidation results in production of byproducts such as acylcarnitines and reactive oxygen species. Acylcarnitines and markers of oxidative stress (e.g., reduced/oxidized glutathione and methionine sulfoxide) are increased in lowlander muscle relative to the Sherpa ([@B45]; [@B65]). However, oxidative damage in lowlanders was reduced to levels comparable with the Sherpa, where acclimatization has taken place ([@B68]). Lactate dehydrogenase activity is elevated in Sherpa muscle ([@B5]; [@B65]), indicating greater capacity for anaerobic lactate production. With increasing altitude, lowlanders experience a gradual reduction in phosphocreatine (PCr) and ATP levels ([@B85]). But the Sherpa maintain PCr and ATP levels at altitude ([@B65]). Thus, the superior muscle energetics displayed by the Sherpa is probably the result of adaptation at the metabolic level.

Birth Weight {#S3.SS6}
------------

Women of European and Han Chinese ancestry exhibit reduced birth weights following gestation at high altitude, quantified at 100 *g* reduction for every 1,000 m elevation ([@B100]; [@B76]; [@B102]). The Sherpa (and Tibetans), however, maintain normal birth weight at both low (1,330 m) and high (3,930 m) altitude ([@B131]; [@B103]). Genes including *PPARA* are expressed in the placenta ([@B9]) and have been shown to influence female reproductive function ([@B23]). HIFs play a critical role in mammalian embryo and placental development ([@B40]; [@B114]). *EPAS1* expression appears reduced in umbilical endothelial cells and placentas of Tibetan women ([@B111]). Intronic variants in *CCDC141* have been shown in Tibetan and Sherpa women to associate with the number of live births, and the same locus also shows evidence of positive selection ([@B74]). The increased reproductive success of the Sherpa is therefore likely to be, at least in part, due to cardiac-related traits ([@B74]) and placental adaptation ([@B27]). Further studies are required to understand the molecular mechanisms by which the Sherpa maintain normal intrauterine growth at altitude.

In summary, the Sherpa display distinct physiological responses to hypoxia that contrast to lowlanders at high altitude ([Table 1](#T1){ref-type="table"}). These are presumably the result of exposure over many generations to the hypoxia-related selective pressure presented by the Tibetan plateau. Indeed, some examples have already emerged of specific genetic signatures of selection associating with distinct adapative traits ([@B127]; [@B101]).

Signatures of Altitude-Related Genetic Selection in the Sherpa {#S4}
==============================================================

With developments in sequencing and genotyping technology over the past decade, it has become possible to identify population-specific signatures of selection for adaptation across the human genome. There are now several complementary genomic tests available for detecting genetic selection ([@B124]) and the application of these tests to data from indigenous high-altitude people including the Sherpa have identified numerous and remarkable genetic signals of selection. Here, we focus on the three most robust signals of selection detected to date in the Sherpa: *EPAS1*, *EGLN1*, and *PPARA* ([Table 2](#T2){ref-type="table"}).

###### 

A summary of genetic adaptations reported in the Sherpa, and replication in other population(s) or species.

  **Genes name(s)**                                                                                                                                                                                               **Sherpa**   **Other population(s) or species**   **Reference(s)**                        
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------ ------------------------------------ --------------------------------------- -------------------------------------------------------------
  ACE                                                                                                                                                                                                             105          [@B39]                               Elite European descent athletes         [@B99]; [@B75]
  *HIF-la*                                                                                                                                                                                                        20           [@B137]                              --                                      --
  *eNOS*                                                                                                                                                                                                          105          [@B38]                                                                       
  *EPAS1*                                                                                                                                                                                                         105          [@B57]                               Tibetan                                 [@B14]; [@B129]; [@B158]; [@B20]; [@B112]; [@B147]; [@B157]
                                                                                                                                                                                                                  51           [@B72]                               Deedu Mongolian                         [@B156]
                                                                                                                                                                                                                  582          [@B19]                               Denisovan                               [@B67]
  3.4 kb Copy Number Deletion-80 kb downstream of *EPAS1*                                                                                                                                                         582          [@B19]                               Tibetan                                 [@B90]
  *EGLN1*                                                                                                                                                                                                         51           [@B72]                               Tibetan                                 [@B88]; [@B129]; [@B158]; [@B155]; [@B89]
                                                                                                                                                                                                                  582          [@B19]                               Andean                                  [@B21]; [@B20]
                                                                                                                                                                                                                  111          [@B159]                              Daghestani                              [@B109]
  *PPARA*                                                                                                                                                                                                         15           [@B65]                               Tibetan                                 [@B129]; [@B112]
                                                                                                                                                                                                                               [@B79]                               (Amhara and Omotic) Ethiopian           [@B123]
  *HYOUI/HMBS*                                                                                                                                                                                                    51           [@B72]                               --                                      --
  *EPAS1*, *EGLN1*, *DLG1*, *MARCH8*, *CDCA7L*, *HEATR5B*, *EDAR*, *ZNF644*, *TTC24*, *TMEM247*, *OXR1*, *ALDH31*                                                                                                 111          [@B159]                              --                                      --
  *NOS1*                                                                                                                                                                                                          111          [@B159]                              Tibetan *(GCH1)*, Andeans (*NOS2*)      [@B21]; \[opetwcitep\]B20,B59\[clotwcitep\][@B20]
  *ANGPT1*                                                                                                                                                                                                        111          [@B159]                              Tibetan and grey wolves of TAR, China   [@B71]; [@B147]
  *EPAS1*, *EGLN1*, *RP11-384F7.2 AC068633.1*, *ZNF53 2*, *HLA-DOB1/HLA-DPB1*                                                                                                                                     10           [@B6]                                --                                      --
  *ANKH*                                                                                                                                                                                                          10           [@B6]                                Pigs of TAR, China                      [@B3]
  *GRB2*                                                                                                                                                                                                          10           [@B6]                                Tibetans                                [@B87]
  Polygeneic Adaptation {Gene subnetworks like the nested integrin associated pathways (i.e., Integrin β-1, Integral α6−β4 and Integrin involved in angiogenesis),CMYB and C-MYC transcription factor pathways}   31           [@B52], [@B51]                       Tibetans                                [@B51]
  *EPAS1, EGLN1.CCDC141,PAPOLA, VRK1, C6orf195, CTBP2, TEX36, EDRF1*                                                                                                                                              103          [@B74]                               Tibetans                                [@B74]

Endothelial PAS Domain-Containing Protein 1 (EPAS1) {#S4.SS1}
---------------------------------------------------

One of the earliest signals for altitude-related adaptation to emerge from genomic selection studies was *EPAS1.* Initially discovered in Tibetans ([@B14]), the *EPAS1* signal has been replicated in multiple other Tibetan populations ([@B20]; [@B129]; [@B158]; [@B112]; [@B147]; [@B157]) as well as the Sherpa ([@B57]; [@B72]; [@B19]). The selected *EPAS1* haplotype is associated with lowered hemoglobin concentrations ([@B14]). Remarkably, it seems the adaptive *EPAS1* haplotype likely descends from an introgression event with the Denisovan people, an extinct species of archaic humans ([@B67]; [@B66]). A 3.4 kb copy number deletion, downstream of *EPAS1*, is elevated in frequency, in Tibetans and Sherpas relative to lowland controls ([@B90]). This deletion is in strong linkage disequilibrium with the previously reported ([@B14]) *EPAS1* haplotype and has also been associated with lower hemoglobin levels. The actual functional *EPAS1* variant(s) that are conferring advantage in relation to hypoxic adaptation remain unknown. However, the intronic and intergenic location of the selected variants would be consistent with a role in HIF-related transcriptional regulation.

*EPAS1* encodes the HIF2 alpha subunit of HIF2. The postnatal deletion of *EPAS1* in adult mice causes anaemia ([@B55]). Some cases of erythrocytosis are caused by missense mutations (e.g., G536W) in *EPAS1* ([@B113]). Mice carrying the *EPAS1* G536W mutation display excessive erythrocytosis and pulmonary hypertension ([@B141]). Another study in heterozygous *EPAS1* knockout mice reported a blunted physiological response to chronic hypoxia ([@B111]). Further *in-vivo* and *in-vitro* studies are necessary to understand how the adaptive version of the *EPAS1* gene is shaping human adaptation to altitude.

Egl-9 Family Hypoxia Inducible Factor 1 (EGLN1) {#S4.SS2}
-----------------------------------------------

Another high altitude genetic selection signal to emerge from early studies on Tibetans was *EGLN1* ([@B129]; [@B158]). Similar to *EPAS1*, this signal was later demonstrated in the Sherpa ([@B72]). Two functional *EGLN1* mutations (rs12097901, D4E, and rs186996510, S127C) appear to be driving the selection signal and are present in both Sherpa ([@B19]) and Tibetans ([@B88]; [@B155]; [@B89]). Whether the mode of action of these two mutations is via gain of function ([@B89]) or loss of function ([@B132]) remains unclear.

*EGLN1* encodes proline hydroxylase 2 (PHD2), an isoform of HIF prolyl-hydroxylase. Homozygous knockout PHD2 mice are unviable and die at the embryonic stage due to severe placental defects ([@B140]). Knockout mice with PHD2 disruption targeted to specific organs including the liver, heart, kidney and lung develop excessive vascular growth ([@B139]). Adult mice deficient for PHD2 display excessive erythrocytosis ([@B138]) and heterozygous PHD2 mice have an increased ventilatory sensitivity to hypoxia and carotid body hyperplasia ([@B22]).

Peroxisome Proliferator-Activated Nuclear Receptor A (PPARA) {#S4.SS3}
------------------------------------------------------------

*PPARA* encodes PPARα, a transcriptional regulator of fatty acid oxidation in liver, heart and muscle ([@B49]). *PPARA* has tissue-specific expression and, under hypoxic conditions, is downregulated by HIFs ([@B106]). Positive selection across the *PPARA* gene has been reported in Tibetans ([@B129]) and Sherpa ([@B65]), and the selected *PPARA* SNPs correlate with reduced hemoglobin levels ([@B129]). Sherpa carriers of the positively selected *PPARA* alleles switch to more efficient fuels such as glucose and display decreased muscular fatty acid oxidation ([@B65]). Most of the *PPARA* SNPs reported to be under selection appear to be non-coding variants ([@B79]). It is unclear if these variants directly affect transcriptional regulation or are linked with functional variants in other genes or nearby inter-genic regions.

Conclusion {#S5}
==========

The Sherpa show remarkable performance in the hypoxic environment presented by high altitude. Comparative physiological studies have suggested numerous distinct, adaptive phenotypes in the Sherpa including advantageous levels of hemoglobin, oxygen saturation and birth weight, and the elevated reproductive success of Sherpa women. Genomic studies have identified robust signals of positive selection across genes including *EPAS1*, *EGLN1* and *PPARA*. All three of these signals of genetic selection have been shown to correlate with advantageous levels of hemoglobin. However, Sherpa-specific signals of genetic selection have also been reported, suggesting that whilst some of the genetic basis for adaptation in the Sherpa is shared with Tibetans, there may be features unique to the Sherpa, which could in turn explain distinct Sherpa phenotypes. Collectively, this illustrates how the outstanding physiological performance of the Sherpa at altitude is, at least in part, a result of hypoxia driven genetic selection spanning the ∼35,000 years of seasonal migration on the Himalayan plateau. Further comparative physiological studies are required to refine existing, and identify additional adaptive phenotypes, in particular those that are specific to the Sherpa. By correlating these phenotypes with known and emerging signals of genetic selection, we can shed light on biological mechanisms of Sherpa hypoxic adaptation. Ultimately this work can inform on treatments of hypoxia-related illness including pulmonary, cardiac, neurological and renal disorders.
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